| Title |
Dosing of chemotherapy in obese and cachectic patients: results of a national survey
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, April 2014
|
| DOI | 10.1007/s11096-014-9942-9 |
| Pubmed ID | |
| Authors |
Helena Anglada-Martínez, Gisela Riu-Viladoms, Fernando do Pazo-Oubiña, Gloria Molas-Ferrer, Irene Mangues-Bafalluy, Carles Codina-Jané, Natàlia Creus-Baró |
| Abstract |
Background It is not unusual to find obese and cachectic patients in the hematology oncology setting. However, information on dosage in these groups is scarce. Objective The objectives of our study were to explore the dosing strategies applied in the treatment of obese and cachectic cancer patients and to determine whether these strategies are applied in clinical trials. Setting Members of the Spanish Group for the Development of Hematology-Oncology Pharmacy (GEDEFO). Methods We invited all cancer hospital pharmacists to participate in a survey. Main outcome measure Descriptive statistics of the dosing strategies approaches. Results We invited 159 eligible hospitals to participate, and 38 responded to the survey. A total of 50 surveys were received: different strategies were applied by different physicians from the same hospital and by hematology and oncology departments. Body mass index was used to define obesity and cachexia in 40 and 30 % of the cases, respectively. Capping the body surface area (BSA) was the approach most commonly followed (64.1 %) in obese patients, whereas no specific approach was adopted in cachectic patients. In hematology patients, the BSA calculation was based on ideal body weight or adjusted body weight in 16.0 % of cases (n = 2) and 50.0 % of cases (n = 6), respectively; in oncology patients, use of adjusted or ideal body weight was negligible. Actual body weight was the main approach in obese patients (35 surveys) and cachectic patients (48 surveys). Creatinine clearance was assessed mainly using the Cockcroft and Gault equation (around 76.0 % of responses). As for clinical trials, 64.1 % of the respondents (n = 25 hospitals) considered the criteria from each clinical trial individually. Conclusions Dose adjustments are more frequent in obese patients than in cachectic patients. In cancer oncology patients, dose is adjusted mainly by hematology and hematopoietic cell transplant teams. Capping BSA is the most frequent strategy, followed by calculating actual body weight. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 22% |
| Unknown | 7 | 78% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 4 | 44% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 21% |
| Student > Master | 3 | 16% |
| Student > Bachelor | 2 | 11% |
| Professor | 2 | 11% |
| Student > Doctoral Student | 2 | 11% |
| Other | 5 | 26% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 26% |
| Nursing and Health Professions | 5 | 26% |
| Medicine and Dentistry | 5 | 26% |
| Economics, Econometrics and Finance | 1 | 5% |
| Unknown | 3 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2014.
All research outputs
#5,837,217
of 22,754,104 outputs
Outputs from International Journal of Clinical Pharmacy
#285
of 1,078 outputs
Outputs of similar age
#54,657
of 226,688 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#4
of 11 outputs
Altmetric has tracked 22,754,104 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,078 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,688 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.